Stanley, W.C., Lopaschuk, G.D., Hall, J.L. and McCormack, J.G. (1997) Regulation of Myocardial Carbohydrate Metabolism under Normal and Ischaemic Conditions. Potential for Pharmacological Interventions. Cardiovascular Research, 33, 243-257.
https://doi.org/10.1016/S0008-6363(96)00245-3

has been cited by the following article:

• TITLE: Effect of Trimetazidine on Functional Capacity in Patient with Ischaemic Cardiomyopathy (TOFCAPI)

  AUTHORS: Mohsin Ahmed, Golam Morshed, Mahmood Hasan Khan, Md. Arifur Rahman, Muhammed Aminur Razzaque, Shariful Islam, Sayeedur Rahman Khan, Chowdhury Md. Kudrat-E-Khuda, Salahuddin Anis Shiblee, Md. Habibur Rahman

  KEYWORDS: Bangladesh, Heart Failure, Exercise Capacity, Trimetazidine, Ischaemic Cardiomyopathy

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.15 No.2, February 26, 2024

  ABSTRACT: Objective: This study aimed to evaluate the efficacy of trimetazidine on exercise capacity via a six-minute walk test in patients with ischaemic cardiomyopathy and also evaluate the effect of trimetazidine on left ventricular function via echocardiography in the same population. Methods: This prospective observational study, conducted at the National Institute of Cardiovascular Diseases in Dhaka, Bangladesh, enrolled 200 patients with ischaemic cardiomyopathy and a depressed left ventricular ejection fraction (LVEF Results: In this study (n = 200) of ischaemic cardiomyopathy patients, the mean age was 58 years, with 76% of the patients being male. All study subjects received GDMT (Guideline-Directed Medical Therapy) for angina and heart failure. Those who received the modified released form of trimetazidine developed lesions during the 1st and 2nd follow-ups, during which the LVEF, LVIDd, and six-minute walk distance significantly improved (p Conclusion: The findings of the present study demonstrated that the addition of modified-release trimetazidine to GDMT can improve exercise capacity and left ventricular function in patients with ischaemic cardiomyopathy.